Cardiovascular Events After CAR T-Cell Therapy for Hematologic Malignant Neoplasms
This meta-analysis assesses the prevalence of ventricular and supraventricular arrhythmias, left ventricular dysfunction, heart failure, myocardial infarction, and death among patients who were treated with chimeric antigen receptor (CAR) T-cell products.